ANG1005 Shows Activity in Patients With Breast Cancer With Leptomeningeal Carcinomatosis and Recurrent Brain Metastases
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
ANG1005, a Brain Penetrating Peptide-Drug Conjugate, Shows Activity in Patients With Breast Cancer With Leptomeningeal Carcinomatosis and Recurrent Brain Metastases
Clin. Cancer Res 2020 Jan 22;[EPub Ahead of Print], P Kumthekar, SC Tang, AJ Brenner, S Kesari, DE Piccioni, CK Anders, JA Carrillo, P Chalasani, P Kabos, SL Puhalla, KHR Tkaczuk, A Garcia, MS Ahluwalia, JS Wefel, N Lakhani, NK IbrahimFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.